ArticleTranslational lung cancer research2026
Real-world effectiveness and safety of adebrelimab as first-line treatment in patients with extensive-stage small cell lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive malignancy. Although immune checkpoint inhibitors (ICIs) combined with chemotherapy have become standard first-line therapy, real-world evidence is necessary to validate clinical trial findings. This study aimed to evaluate the real-world effectiveness and safety of adebrelimab-based therapy in Chinese patients with ES-SCLC. Methods: In this prospective, multicenter real-world study, patients with histologically or cytologically confirmed ES-SCLC received an adebrelimab-based regimen. The primary outcome was progression-free survival (PFS); secondary outcomes included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Cox regression analyses were performed to identify prognostic factors. Results: From February 2023 to July 2024, a total of 170 patients were enrolled. The median age was 69 years. None of the patients had received prior systemic therapy. The ORR was 69.4%, and the DCR was 89.4%. The median PFS (mPFS) was 7.03 months [95% confidence interval (CI): 6.08-8.05], and the median OS (mOS) was 14.29 months (95% CI: 11.89-17.12). Multivariate analysis showed that liver metastasis [hazard ratio (HR) =1.852, P=0.006], lactate dehydrogenase (LDH) greater than the upper limit of normal (ULN) (HR =1.704, P=0.046), hypertension (HR =1.578, P=0.03), and grade ≥3 adverse events (AEs) (HR =1.590, P=0.050) were independently associated with PFS. For OS, advanced age and liver metastasis (both P<0.05) remained significant prognostic factors. Treatment-related AEs occurred in 96.5% of patients, with grade ≥3 AEs in 19.4%. Conclusions: Adebrelimab-based therapy demonstrated promising real-world effectiveness and a manageable safety profile in patients with ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.